Meningococcal polysaccharide vaccine Side Effects
Medically reviewed by Drugs.com. Last updated on Nov 16, 2020.
For the Consumer
Applies to meningococcal polysaccharide vaccine: parenteral solution for im use
Side effects include:
MenACWY-CRM (Menveo®): Injection site reactions (tenderness, erythema), irritability, sleepiness, persistent crying, change in eating habits, vomiting, diarrhea in infants 2 through 23 months of age; injection site reactions (pain, erythema, induration), irritability, sleepiness, malaise, headache in children 2 through 10 years of age; injection site pain, headache, myalgia, malaise, nausea in adults and adolescents.
For Healthcare Professionals
Applies to meningococcal polysaccharide vaccine: subcutaneous powder for injection
The most common adverse events were injection site pain, headache, irritability, and diarrhea.[Ref]
Very common (10% or more): Injection site pain (48.1%), injection site redness (16%), injection site induration (11%), injection site tenderness
Common (1% to 10%): Injection site swelling, injection site hematoma
Uncommon (0.1% to 1%): Injection site reaction
Rare (less than 0.1%): Severe local reactions
Postmarketing reports: Extensive limb swelling at the injection site (frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb)[Ref]
Very common (10% or more): Headache (41.8%), drowsiness (11.2%)
Uncommon (0.1% to 1%): Hypoesthesia, dizziness
Very rare (less than 0.01%): Somnolence, neurological reactions
Very common (10% or more): Fatigue (32.3%), malaise (22.3%), fever
Common (1% to 10%): Chills, febrile reactions (>38C)
Very common (10% or more): Irritability (12.2%)
Very common (10% or more): Arthralgia (16%)
Uncommon (0.1% to 1%): Myalgia, pain in extremity
Postmarketing reports: Musculoskeletal stiffness[Ref]
Very common (10% or more): Appetite lost
Common (1% to 10%): Anorexia
Postmarketing reports: Decreased appetite[Ref]
Very common (10% or more): Diarrhea (14%)
Common (1% to 10%): Vomiting, nausea[Ref]
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus
Uncommon (0.1% to 1%): Upper respiratory tract illness
Rare (less than 0.1%): Wheeze[Ref]
Postmarketing reports: IgA nephropathy[Ref]
More about meningococcal polysaccharide vaccine
Related treatment guides
1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. "Product Information. Menomune (meningococcal polysaccharide vaccine)." Sanofi Pasteur, Toronto, IA.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.